Our partnering work

JPG works closely with the JPMA – we seek to bring the global voice closer to UK decision-making and do this in a number of ways: including through responses to consultations, attitudinal research and bilateral meetings.

In 2024 we were delighted to collaborate with the Japan Society in hosting a parliamentary reception for a JPMA delegation led by its Vice President, Dr Sunao Manabe, CEO of Daiichi Sankyo. Guests at the reception were given copies of a JPMA Communique that had been presented to Lord Patrick Vallance, earlier in the day.

“JPMA highly values the UK as one of the few countries with a clear and continued pro-IP position, supported by clear pro-innovation policies with a number of initiatives and funds to support the industry. Whilst the commercial landscape within the UK is seen as increasingly challenging, we remain optimistic that there is a significant opportunity to work collaboratively to drive investment and make progress on the Government’s growth ambitions”.

“Access to medicines is one of the key drivers of investment decisions and the UK continues to fall behind comparable countries when it comes to patients benefitting from new medicines. There needs to be a strong and symbiotic R&D and commercial environment for innovative sectors to thrive.”

“In summary we urge the Government to implement strategies related to streamlining regulation and improving access and uptake of medicines. We believe this would help to create an environment that: fosters innovation, leads to early access to innovation for UK patients; supports new collaborations for the NHS and subsequent improvements in healthcare; and drives economic growth from life science investment into the UK”

Our goal with the survey was to provide the Government with useful insights that can contribute to the development of its Life Sciences Strategy. It covers prospects for future Japanese investment, key factors influencing investment and recommendations for rebooting the UK Life Sciences Strategy.